ST Landfar plans to acquire 51% equity of Huize Pharmaceutical, which is expected to constitute a significant asset restructuring situation
Landfar plans to acquire 51% equity of Hunan Huize Pharmaceutical in cash, which is expected to constitute a major asset reorganization. After the transaction, Huize Pharmaceutical will become a subsidiary and be included in the consolidated financial statements. Huize Pharmaceutical focuses on drug research and development as well as clinical evaluation, providing pharmaceutical research, clinical trials, and other services. This acquisition aims to enhance the profitability and risk resistance of the biopharmaceutical sector and improve the company's operational efficiency
According to the Zhitong Finance APP, *ST Landfar (000504.SZ) announced that the company is planning to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. (hereinafter referred to as "Huize Pharmaceutical" or "the target company") in cash. Upon completion of this transaction, Huize Pharmaceutical will become a controlling subsidiary of the company and will be included in the consolidated financial statements. According to preliminary estimates, this transaction is expected to constitute a major asset restructuring as defined by the "Administrative Measures for Major Asset Restructuring of Listed Companies."
Huize Pharmaceutical is a professional CRO company focused on drug research and clinical evaluation, providing services mainly including pharmaceutical research, clinical trials, bioanalysis, and data management statistical analysis.
Before this transaction, the listed company mainly engaged in two business segments: "biomedical" and "energy conservation and environmental protection," as well as the production and sales or agency sales of other biomedical-related products. Among them, the "biomedical" segment mainly includes stem cell storage and technology services, stem cell application research, and the procurement and sales of medical devices.
The acquisition of Huize Pharmaceutical aims to extend the development of the listed company's biomedical segment, thereby further enhancing the profitability of the company's main business and improving its risk resistance capability. On the other hand, there is a strong correlation between cell clinical transformation research and drug research and clinical evaluation business. Through asset integration, it will be beneficial to improve the company's operational efficiency and has strong synergy effects
